These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

792 related items for PubMed ID: 18956293

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
    Choi SS, Diehl AM.
    Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pathogenesis of nonalcoholic steatohepatitis (NASH).
    Ma X, Li Z.
    Chin J Dig Dis; 2006 Jun; 7(1):7-11. PubMed ID: 16412031
    [Abstract] [Full Text] [Related]

  • 6. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.
    Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD.
    Gastroenterology; 2007 Jul; 133(1):80-90. PubMed ID: 17631134
    [Abstract] [Full Text] [Related]

  • 7. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.
    Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, Onori P, Alvaro D, Gaudio E.
    Hepatology; 2012 Dec; 56(6):2142-53. PubMed ID: 22467277
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis.
    Rombouts K, Marra F.
    Dig Dis; 2010 Dec; 28(1):229-35. PubMed ID: 20460917
    [Abstract] [Full Text] [Related]

  • 10. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE.
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT, de Oliveira CP, Corrêa-Giannella ML, Soares IC, Kubrusly MS, Bellodi-Privato M, de Mello ES, de Lima VM, Carrilho FJ, Alves VA.
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [Abstract] [Full Text] [Related]

  • 14. Recent advances in nonalcholic fatty liver disease.
    Greenfield V, Cheung O, Sanyal AJ.
    Curr Opin Gastroenterol; 2008 May; 24(3):320-7. PubMed ID: 18408460
    [Abstract] [Full Text] [Related]

  • 15. Activin A in nonalcoholic fatty liver disease.
    Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P.
    Vitam Horm; 2011 May; 85():323-42. PubMed ID: 21353887
    [Abstract] [Full Text] [Related]

  • 16. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective.
    Lackner C.
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):223-31. PubMed ID: 21476917
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A human hepatocellular in vitro model to investigate steatosis.
    Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, O'Connor JE.
    Chem Biol Interact; 2007 Jan 30; 165(2):106-16. PubMed ID: 17188672
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D, Schattenberg JM.
    J Gastroenterol Hepatol; 2013 Aug 30; 28 Suppl 1():68-76. PubMed ID: 23855299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.